Phase II study shows that significantly fewer rhIL-11 treated patients require platelet transfusions.
D000970:Antineoplastic Agents / Q000009:adverse effects*; D017322:Clinical Trials, Phase II as Topic; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007279:Injections, Subcutaneous; D017370:Interleukin-11 / Q000627:therapeutic use*; D008223:Lymphoma / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy; D017713:Platelet Transfusion; D011994:Recombinant Proteins; D013921:Thrombocytopenia / Q000139:chemically induced / Q000517:prevention & control*
D000970:Antineoplastic Agents; D017370:Interleukin-11; D011994:Recombinant Proteins